The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Autologous transplantation versus DaraVCD in patients with AL amyloidosis
Meral Beksac, MD, Ankara University, Ankara, Turkey, describes the results of a single center study comparing autologous stem cell transplantation (autoSCT) versus daratumumab, bortezomib, cyclophosphamide and dexamethasone (DaraVCD) for patients with light chain (AL) amyloidosis. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Oncopeptides: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
